NOVT Stock Forecast: Novanta, Inc. Price Predictions for 2026-2027
The 3 Wall Street analysts covering Novanta, Inc. hold a median 12-month price target of $185 — +81.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 28 of 100 as at 20 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Novanta, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (70): Analysts have, on balance, been raising their forecasts.
Issuance (17): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
NOVT stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on NOVT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +81.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Nov 2026 | Baird | Maintains | Outperform | $194 → $175 |
| 13 May 2026 | Baird | Maintains | Outperform | $144 → $173 |
| 30 Mar 2026 | Baird | Upgrade | Outperform | — |
| 11 Aug 2025 | Baird | Maintains | Neutral | — |
| 3 Mar 2025 | Baird | Maintains | Neutral | — |
| 6 Nov 2024 | Baird | Maintains | Neutral | — |
| 7 Aug 2024 | Baird | Maintains | Neutral | — |
| 11 May 2023 | Baird | Maintains | Neutral | — |
| 11 May 2022 | William Blair | Upgrade | Outperform | — |
| 13 Nov 2020 | Berenberg | Initiates | Hold | — |
| 13 May 2020 | Baird | Maintains | Neutral | — |
| 28 Feb 2019 | Baird | Maintains | Neutral | — |
| 9 May 2018 | Baird | Downgrade | Neutral | — |
| 27 Feb 2018 | William Blair | Initiates | Outperform | — |
| 8 Dec 2017 | Baird | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for NOVT.
This page is one stock. Monday covers all of them.
NOVT appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
NOVT vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Novanta, Inc. returned +2.8% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
NOVT analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 77.9×
- Price / sales
- 3.6×
- Price / book
- 2.4×
- EV / EBITDA
- 25.3×
Cheaper than 11% of US stocks
Cheaper than 30% of US stocks
Cheaper than 38% of US stocks
Cheaper than 15% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- −81.1%
- Gross margin
- 45.5%
- Operating margin
- 11.8%
- Net margin
- 4.9%
Higher than 5% of US stocks
Higher than 56% of US stocks
Higher than 66% of US stocks
Higher than 56% of US stocks
- Return on equity
- 4.4%
- Return on assets
- 3.4%
- Dividend yield
- —
Higher than 51% of US stocks
Higher than 67% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Novanta, Inc. has a market value of $4.3B and an enterprise value of $5.1B.
Revenue in the twelve months to 30 June 2026: $1.0B. The latest quarter grew 10.3% year on year.
Net income over the same four quarters: $61.8M, a 6.0% net margin.
Diluted earnings per share, trailing twelve months: $1.56.
Free cash flow in the twelve months to 30 June 2026: $114.3M.
Novanta, Inc. spent $51.8M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 77.9×; forward P/E: 24.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Novanta, Inc. employs 3,000 people — $343K of revenue per employee.
Data provided by Twelve Data
NOVT and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at NOVT’s peer groups, ranked by the model: industrial stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Novanta, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about NOVT
What is the NOVT stock price forecast for 2026-2027?
The 3 Wall Street analysts covering Novanta, Inc. have a median 12-month price target of $185, with estimates ranging from $175 to $195. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is NOVT stock a buy right now?
Of the 3 analysts covering Novanta, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Novanta, Inc. 28 out of 100 across roughly 4,300 US stocks as at 20 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank NOVT?
As at 20 Nov 2026, Novanta, Inc. ranks 28 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (70 of 100).
Will NOVT stock go up?
No one can know that. What the data says: the median 12-month target from 3 analysts implies +81.4% from the last close, and Ticker Nerd's factor model ranks Novanta, Inc. 28 out of 100 as at 20 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the NOVT stock forecast for 2030?
No analyst covering Novanta, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NOVT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $175 to $195 over the next 12 months.
How has NOVT stock performed over the past year?
Novanta, Inc. returned +2.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Novanta, Inc. do?
Novanta Inc. is a global technology company that provides core solutions for medical and advanced industrial equipment manufacturers. Novanta designs and manufactures precision photonics, vision, and motion control components and subsystems used in applications such as laser processing, robotics, automation, metrology, and scientific instrumentation.
About Novanta, Inc.
Novanta Inc. is a global technology company that provides core solutions for medical and advanced industrial equipment manufacturers. Novanta designs and manufactures precision photonics, vision, and motion control components and subsystems used in applications such as laser processing, robotics, automation, metrology, and scientific instrumentation. The company also supplies medical technologies for surgical imaging, visualization, identification, and other clinical workflows, supporting original equipment manufacturers across healthcare and life science markets. Novanta operates through its Automation Enabling Technologies and Medical Solutions segments, serving customers in North America, Europe, and Asia Pacific. Headquartered in Bedford, Massachusetts, Novanta focuses on mission-critical technologies that help its customers build highly specialized systems requiring precision, reliability, and performance.
CEO Mr. Matthijs Glastra · 3,000 employees · United States · https://www.novanta.com